Literature DB >> 3033259

The effect of oropharyngeal decontamination using topical nonabsorbable antibiotics on the incidence of nosocomial respiratory tract infections in multiple trauma patients.

C P Stoutenbeek, H K van Saene, D R Miranda, D F Zandstra, D Langrehr.   

Abstract

The incidence of respiratory tract infections was determined in 59 multiple trauma patients requiring prolonged intensive care (greater than 5 days) and receiving no antibiotic prophylaxis. Early pneumonia (less than 48 hr) with S. aureus, S. pneumoniae, and/or H. influenzae was found in 44% of patients. Secondary colonization of the oropharynx and respiratory tract with ICU-associated Gram-negative bacilli followed by pneumonia occurred in 12 patients (20%). The overall incidence of respiratory tract infections was 59%. In a prospective open trial three prophylactic antibiotic regimens were compared: 17 patients were treated with intestinal decontamination using nonabsorbable antibiotics (polymyxin E 400 mg, tobramycin 320 mg, amphotericin B 2,000 mg/day). No difference in infection rate was found. Twenty-five patients were treated with intestinal and oropharyngeal decontamination using an ointment containing 2% of the same antibiotics. Secondary colonization and infection of the respiratory tract with Gram-negative bacilli was significantly reduced (p less than 0.001). The incidence of early (Gram-positive) infections, however, was unchanged. Another group of 63 patients was treated with systemic antibiotic prophylaxis during the first days in combination with oropharyngeal and intestinal decontamination. The incidence of early pneumonia was significantly reduced (p less than 0.001). Five patients (8%) developed an infection. Superinfections were not observed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033259     DOI: 10.1097/00005373-198704000-00003

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  41 in total

Review 1.  All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth.

Authors:  Hendrick K F van Saene; Andy J Petros; Graham Ramsay; Derrick Baxby
Journal:  Intensive Care Med       Date:  2003-04-10       Impact factor: 17.440

2.  Case report medication error: oral antibiotics and simethicone accidentally injected intravenously.

Authors:  Rolf C Mahne; Johan Damen; Frank G A Jansman
Journal:  Intensive Care Med       Date:  2003-06-12       Impact factor: 17.440

3.  Uncertain relevance of gastric colonization in the seriously ill.

Authors:  J F Cade; E McOwat; R Siganporia; C Keighley; J Presneill; V Sinickas
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

4.  Comment on Short-term parenteral antibiotics used as a supplement to SDD regimens (Infection Suppl. 1, 1990, S14-S17). Reply to F. Daschner (Infection 18 [1990] 249)

Authors: 
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

Review 5.  Pharmacoeconomics of selective decontamination of the digestive tract in intensive care patients: a US perspective.

Authors:  S J Markowsky; J Christie
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

6.  Selective decontamination of the digestive tract.

Authors: 
Journal:  BMJ       Date:  1990-01-20

7.  Selective decontamination of the digestive tract.

Authors: 
Journal:  BMJ       Date:  1990-02-17

8.  How to improve infection prevention by selective decontamination of the digestive tract (SDD).

Authors:  C P Stoutenbeek; H K van Saene
Journal:  Infection       Date:  1990       Impact factor: 3.553

9.  Dose-dependent rate of nosocomial pulmonary infection in mechanically ventilated patients with brain oedema receiving barbiturates: a prospective case study.

Authors:  K E Eberhardt; B M Thimm; A Spring; W R Maskos
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

Review 10.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.